Immune modulatory nanoparticle therapeutics for intracerebral glioma.

ABSTRACT:

Background

Previously we showed therapeutic efficacy of unprotected miR-124 in preclinical murine models of glioblastoma, including in heterogeneous genetically engineered murine models by exploiting the immune system and thereby negating the need for direct tumor delivery. Although these data were promising, to implement clinical trials, we required a scalable formulation that afforded protection against circulatory RNases.

Methods

We devised lipid nanoparticles that encapsulate and protect the miRs from degradation and provide enhanced delivery into the immune cell compartment and tested in vivo antitumor effects.

Results

Treatment with nanoparticle-encapsulated miR-124, LUNAR-301, demonstrated a median survival exceeding 70 days, with an associated reversal of tumo

SUBMITTER: Yaghi NK 

PROVIDER: S-EPMC5464307 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature